ASH 2020: Results of a study examining lenalidomide combined with chemoimmunotherapy for first line treatment of DLBCL.
Home / Resource Library / Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E